Antibodies to CD40 induce a lethal cytokine cascade after syngeneic bone marrow transplantation  by Hixon, Julie A et al.
136
INTRODUCTION
CD40 is a member of the nerve growth factor/tumor
necrosis factor (TNF) receptor superfamily of molecules,
which includes fas and CD30 [1,2]. Although the expres-
sion of CD40 was initially thought to be restricted to
B lymphocytes, it is now known that CD40 is widely dis-
tributed on a variety of cell types, including antigen-
presenting cells (ie, monocytes, dendritic cells), hemato-
poietic progenitor cells, endothelial cells, and carcinomas
[3]. Signaling through the CD40 receptor can have either
activating or inhibitory effects, depending on the cell type.
In normal, untransformed cells, CD40 stimulation leads to
activation of monocytes and T cells, resulting in the gener-
ation of efficient immune responses [3,4]. The critical role
of CD40 in immune function can also be attributed to
increases in B-cell proliferation and maturation; an
increase in co-stimulatory molecules such as intercellular
adhesion molecule 1, B7-1, and B7-2; an increase in anti-
gen presentation; and secretion of important inflammatory
cytokines, such as interleukin (IL)-1, IL-6, and TNF-α
from B cells and macrophages [3]. Although stimulation of
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ABSTRACT
CD40 stimulation, by either antibody or ligand, has been shown to inhibit the growth of a variety of neoplastic cells,
both in vivo and in vitro. In this study, we assessed the effects of CD40 stimulation using a murine agonistic CD40
monoclonal antibody (MoAb) (FGK115) or a soluble recombinant murine CD40 ligand (srmCD40L) in both lethally
irradiated and nonirradiated BALB/c mice. Toxicity after CD40 stimulation was not observed in nonirradiated ani-
mals receiving up to 100 µg of the agonist anti-CD40 MoAb. However, as little as 10 µg of the agonistic anti-CD40
MoAb induced acute toxicity resulting in 100% morbidity of lethally irradiated animals by 4 days after irradiation.
Histological evaluation of animals receiving anti-CD40 MoAb revealed severe intestinal lesions with disruption of the
villi, goblet cell depletion, and crypt hyperplasia of the small intestine, colon, and cecum. Delaying the administration
of anti-CD40 MoAb or reducing the amount of irradiation given resulted in increased survival and less severe
lesions. Analysis of serum cytokine levels in lethally irradiated mice receiving agonistic anti-CD40 showed a marked
increase of interferon (IFN)-γ. Lethally irradiated IFN-γ knockout mice given the agonistic anti-CD40 MoAb demon-
strated significant increases in survival and minimal gut lesions compared with wild-type mice receiving the same
regimen, suggesting that IFN-γ plays a major role in this toxic reaction. These results indicate that CD40 stimulation
using agonistic antibodies following lethal irradiation leads to a fatal, cytokine-induced disease affecting the intestine.
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CD40 on the surface of normal cells has an activating
effect, triggering of CD40 on transformed cells can result
in the transduction of negative signals that inhibit the
growth of lymphomas [5-7] and solid tissue carcinomas
[8,9]. High levels of expression of CD40 on a variety of
human carcinomas, including bladder, breast, ovarian, and
melanomas, makes it an attractive target for tumor therapy
[10,11]. We have previously shown that CD40 stimulation,
both in vitro and in vivo, results in antitumor activity with-
out adverse affects in both human lymphoma [6] and carci-
nomas [9] placed in immunodeficient mice.
Our previous studies were performed using human anti-
bodies in a mouse model, which prevented assessment of the
effects of anti-CD40 monoclonal antibody (MoAb) adminis-
tration on normal tissue. We have demonstrated that adminis-
tration of a srmCD40L can increase lymphoid and myeloid
recovery after syngeneic bone marrow transplantation (BMT)
in mice. Antibodies to murine CD40 have been given to non-
irradiated mice with no overt toxicity being reported [5-7].
Because CD40 is widely distributed on lymphocytic,
endothelial, and hematopoietic cell types, the effects of anti-
bodies to CD40 on these normal cell populations must be
considered. Conventional cancer therapy commonly uses
irradiation, either alone or in combination with chemo-
therapy, to reduce the tumor burden in the host. Dramatic
changes in cytokine proﬁles after irradiation therapy could
potentially alter the expression of CD40 on normal tissues,
thereby creating an environment for potentially toxic effects
that would not be seen in the nonirradiated host. This study
assesses the effects of an agonistic, murine monoclonal CD40
antibody in normal, non–tumor-bearing mice, both in nonir-
radiated animals and in animals that received lethal total body
irradiation (TBI). This model will allow for the evaluation of
potential toxicity associated with CD40 stimulation alone or
in combination with conventional cancer therapy.
MATERIALS AND METHODS
Mice
Female BALB/c and male and female BALB/c interferon
(IFN)-γ knockout mice were obtained from the Animal Pro-
duction Area (National Cancer Institute-Frederick Cancer
Research and Development Center [NCI-FCRDC], Freder-
ick, MD) and were not used until 8 weeks of age. Animals
were cared for humanely according to the US Public Health
Policy on the Care and Use of Animals, and the Guide for the
Care and Use of Laboratory Animals. NCI-FCRDC facilities
are accredited by the Association for Assessment and Accredi-
tation of Laboratory Animal Care International.
Antibodies and srmCD40 Ligand
Anti-mouse CD40 (FGK115, rat immunoglobulin G1
agonistic MoAb) was produced as ascites, as described previ-
ously [5]. The antibody was at a concentration of 7.8 mg/mL,
kept frozen until use, and diluted in phosphate-buffered
saline (PBS) for injections. Trimeric recombinant soluble
murine CD40 ligand (CD40L)/leucine-zipper fusion pro-
tein (srmCD40L) was generously donated by Immunex
(Seattle, WA) and was prepared as previously described [6].
The ligand was at a concentration of 1.29 mg/mL, kept
frozen until use, and diluted in PBS for injections.
Bone Marrow Transplantation
Recipient BALB/c or BALB/c IFN-γ knockout mice
were exposed to a 137Cesium source at a dose rate of
212 cGy/min and received 750 cGy TBI. Mice were then
given 106 syngeneic bone marrow cells (BMC) intra-
venously. Additional studies were performed to evaluate the
role of irradiation in CD40-induced toxicity. For these stud-
ies, mice were exposed to either 800 cGy, 700 cGy, or
600 cGy, and given 106 syngeneic BMC intravenously. After
irradiation and transplantation in both model systems, the
mice received either murine agonistic monoclonal CD40,
clone FGK115 (1-100 µg), murine srmCD40L (10 or
100 µg), or normal rat serum control in 0.2 mL PBS intraperi-
toneally (IP), beginning at either day 0, 1, or 2 and continuing
daily for a total of 4 injections. All experiments were assayed
with 6 to 12 mice per group and were performed 2 to 6 times,
with a representative experiment being shown.
Histology
Either a complete necropsy was performed, or selected
organs were examined, including small intestine, colon,
lungs, and liver, were fixed in 10% formalin. Gut was
collected in a “swiss roll” for microscopic examination of
maximal surface area. Tissues were embedded in paraffin,
sectioned at 5 µm, and stained with hematoxylin and eosin.
Slides were evaluated microscopically by a veterinary
pathologist without reference to the various treatment
groups. Grading was as follows: 1, minimal; 2, mild; 3, mod-
erate; 4, severe; M, missing; P, present; —, no significant
lesion. The experiments were performed 2 to 8 times, with a
representative being shown.
Serum IFN-γ Determination
For determination of serum IFN-γ levels, blood was col-
lected after 4 injections of either agonistic anti-CD40
MoAb, srmCD40L, or control sera. Samples were assayed
by enzyme-linked immunosorbent assay (ELISA) using a
Quantikine M mouse IFN-γ Immunoassay Kit (R&D Sys-
tems, Minneapolis, MN). The assay was performed accord-
ing to instructions from the manufacturer.
RESULTS
Stimulation Via Agonistic CD40 MoAb Induces Rapid
Toxicity in Lethally Irradiated Mice
Administration of anti-CD40 MoAb is effective in eradi-
cating tumors in lymphoma-bearing mice [7]. However, anti-
tumor therapy often includes irradiation to reduce tumor
burden in the host. We have previously shown no adverse
effects using an srmCD40L after BMT in mice [12], but the
effects of murine agonistic MoAb to CD40 (FGK115) have
not been similarly evaluated in the setting of lethal TBI.
Therefore, we ﬁrst examined the effects of CD40 stimulation
in nonirradiated BALB/c mice, and we found that adminis-
tration of up to 100 µg of this agonistic CD40 MoAb
expanded the lymphocytic compartment without any adverse
effects (J.A.H., B.R.B., M.R.A., R.H.W., W.J.M., unpub-
lished data). To evaluate the effects of an agonistic CD40
MoAb after BMT, syngeneic BMC were transferred into
lethally irradiated (750 cGy) BALB/c recipients, and the
mice were given either anti-CD40 MoAb (FGK115),
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srmCD40L, or control sera (1-100 µg IP daily for 4 days),
beginning the day of the irradiation and transplantation.
Surprisingly, all mice receiving either 10 µg or 100 µg of
anti-CD40 MoAb died within 4 days after lethal TBI (Fig-
ure 1). However, 1 µg anti-CD40 MoAb had no effect on
survival (data not shown). Similarly, other strains of mice
such as C57BL6 that were lethally irradiated died rapidly
after administration of 100 µg of anti-CD40 MoAb (data
not shown). However, mice receiving up to 100 µg of
srmCD40L demonstrated no adverse affects at this same
dose and schedule (Figure 1). The cause of mortality in both
the BALB/c and C57BL6 mice receiving agonistic CD40
MoAb were severe intestinal lesions (Table 1). The small
intestine had lesions throughout its entire length. Villi were
severely blunted, distorted, and fused, with patchy epithelial
vacuolation. Crypt cells were distorted and more hyperplas-
tic than in mice that did not receive anti-CD40 MoAb (Fig-
ure 2). The large bowel of mice receiving anti-CD40 MoAb
had extensive goblet cell depletion. Crypt cells had multifo-
cal karyomegaly, piled up nuclei, and hyperplasia (Figure 3).
There were no life-threatening lesions in the liver, kidney,
brain, lung, heart, or spleen (data not shown). In addition,
histological evaluation of mice receiving up to 100 µg of
srmCD40L revealed only minimal to mild pathological
changes in the gut (Table 1). These results demonstrate that
administration of an agonistic CD40 MoAb (FGK115) after
lethal TBI and syngeneic BMT induces rapid morbidity
caused by significant destruction of gut tissue that is not
seen in control animals or in mice treated with srmCD40L.
Delayed Administration of Agonistic CD40 MoAb 
or Reduction of Total Body Irradiation Eliminates 
Anti-CD40 Induced Toxicity
We next investigated whether delaying the administra-
tion of anti-CD40 MoAb or reducing the amount of irradia-
tion given inﬂuenced the morbidity seen after CD40 stimu-
lation. To assess whether the scheduling of anti-CD40 MoAb
administration influenced survival and gut damage after
lethal TBI, syngeneic BMC were transferred into recipient
BALB/c mice that had been lethally irradiated. Anti-CD40
MoAb (10 µg IP) was then administered daily, beginning at
either day 0, 1, or 2, and continued for a total of 4 injections.
All mice receiving agonistic anti-CD40 MoAb at day 0 died
by day 4, and 80% of mice receiving anti-CD40 MoAb at
day 1 died by day 7 (Figure 4). All mice receiving anti-CD40
MoAb beginning on day 2 survived (Figure 4). Histological
evaluation of gut tissue removed from animals receiving anti-
CD40 MoAb at day 0 again demonstrated severe disruption
of normal gut architecture, including crypt cell hyperplasia,
goblet cell depletion, and villous blunting and fusion,
whereas mice receiving anti-CD40 MoAb beginning on day
1 showed moderate, but signiﬁcantly fewer, changes in gut
lesions compared with mice treated at day 0 (data not
shown). These data demonstrate that delaying CD40 stimu-
lation after lethal TBI reduces gut lesions and eliminates
anti-CD40–induced lethality.
To ascertain the role of TBI in CD40-induced toxicity,
recipient BALB/c mice were given either lethal or sublethal
doses of irradiation, followed by transfer of syngeneic BMC
and daily 10 µg injections of agonistic anti-CD40 MoAb
(FGK115), beginning at day 0, with a total of 4 injections
being given. Administration of anti-CD40 MoAb after lethal
doses of irradiation (800 or 700 cGy) resulted in rapid mor-
bidity, with most mice dying within 4 days (Figure 5). Inter-
estingly, administration of sublethal doses of irradiation
(600 cGy) in combination with anti-CD40 MoAb treatment
resulted in the survival of all animals (Figure 5). Histological
Figure 1. Stimulation of CD40 with agonistic CD40 murine monoclo-
nal antibody (MoAb) (FGK115) induces acute, lethal toxicity. BALB/c
mice were given 750 cGy total body irradiation (TBI) and syngeneic
bone marrow transplantation followed by daily intraperitoneal injec-
tions of either control sera, 10 µg anti-CD40 MoAb, or 100 µg of
srmCD40L for 4 days. All mice receiving anti-CD40 MoAb demon-
strated signiﬁcant (P < .0001) mortality by day 3, whereas 100% of mice
receiving either srmCD40L or control sera survived. Data presented are
a combination of 2 experiments containing 4 to 8 mice per group.
Table 1. Effect of Administration of Anti-CD40 MoAb on the Gut After Total Body Irradiation and BMT*
Control Control Anti-CD40 Anti-CD40 Anti-CD40 Anti-CD40 srmCD40L srmCD40L
Colon
Crypt cell hyperplasia — 1 3 2 2 2 — —
Goblet cell depletion — — 4 4 4 4 — —
Crypt karyomegaly — — 3 2 2 — — —
Small intestine
Villous blunting 2 2 4 4 3 4 — —
Villous fusion 2 2 4 4 3 4 — —
*BALB/c mice were lethally irradiated and given a syngeneic bone marrow transplantation (BMT), followed by daily intraperitoneal injections of
either control serum, 10 µg of anti-CD40 monoclonal antibody (MoAb), or 100 µg of srmCD40L for 4 days. Mice were killed for histological evalu-
ation 24 hours after the last intraperitoneal injection. Lesions were evaluated and scored as follows: 1, minimal; 2, mild; 3, moderate; 4, severe; —,
no signiﬁcant lesion. Experiments were performed twice with similar results. Data represent individual mice. 
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analysis showed a lessening of the pathological changes
observed in the gut tissues of mice receiving sublethal doses
of irradiation compared with mice receiving lethal doses of
irradiation as a response to anti-CD40 MoAb treatment
(Table 2). Thus, the intensity of conditioning, as well as
delaying administration of anti-CD40 MoAb, inﬂuences both
morbidity and lesions in mice receiving antibodies to CD40.
Administration of Anti-CD40 MoAb Increases IFN-γ
Levels in the Serum of Mice That Have Been Lethally
Irradiated
IFN-γ has been previously shown to increase CD40
expression on normal monocytes and to prime monocytes for
the secretion of multiple inﬂammatory cytokines, including
TNF-α, IL-6, and IL-12, after CD40 stimulation [3,13,14].
Therefore, the role of cytokines in the CD40-induced toxic-
ity observed after lethal TBI and syngeneic BMT was evalu-
ated. Either nonirradiated or lethally irradiated (750 cGy)
BALB/c mice received a syngeneic BMT. They were then
injected daily with either agonistic anti-CD40 MoAb
(10 µg), srmCD40L (10 or 100 µg) or control serum, begin-
ning at day 0 and continuing for 4 days. Serum was collected
from the mice at day 4, and IFN-γ levels were assessed by
ELISA. Results from these experiments demonstrated a
marked and significant (P = .001) increase in the level of
IFN-γ in the serum of lethally irradiated mice receiving
10 µg of agonistic CD40 MoAb compared with control animals
after 4 injections of anti-CD40 MoAb (Table 3). Interestingly,
an increase in IFN-γ was not observed either in nonirradiated
mice receiving 10 µg of anti-CD40 MoAb or in lethally irra-
diated mice receiving control sera or up to 100 µg of
srmCD40L after 4 injections of either antibody or ligand
(Table 3). This suggests that IFN-γ may play a role in the
morbidity and lesion development observed after anti-CD40
MoAb stimulation in lethally irradiated recipients.
Absence of IFN-γ Significantly Improves Survival of
Lethally Irradiated Recipients Receiving Anti-CD40
MoAb
Because only agonistic CD40 MoAb induced high levels
of serum IFN-γ in lethally irradiated recipients, we speculated
that the toxicity of anti-CD40 MoAb would be reduced in the
absence of IFN-γ. Therefore, lethally irradiated BALB/c
IFN-γ knockout recipients given 106 BMC from IFN-γ
knockout donors and wild-type BALB/c control recipients
given 106 BMC from wild-type donors were treated with
Figure 2. Anti-CD40 monoclonal antibody (MoAb)–induced toxicity is mediated by destruction of the small intestine. BALB/c mice received
750 cGy and underwent syngeneic bone marrow transplantation followed by daily intraperitoneal injections of either 10 µg anti-CD40 MoAb or
control serum for 4 days. Mice underwent complete necropsy 24 hours after the last intraperitoneal injection. A and C, BALB/c mouse treated with
control serum. Small intestine has normal length villi (v) and slight crypt cell hyperplasia (c) (A and C, hemotoxylin and eosin stain, original magniﬁ-
cations ×33 and ×66, respectively). B and D, BALB/c mice treated with anti-CD40 MoAb. Small intestine has severely blunted and fused villi (v)
with vacuolated cytoplasm (arrows) and distorted, hyperplastic crypts (c) (B and D, hemotoxylin and eosin stain, original magniﬁcations ×33 and
×66, respectively). Experiments were performed 8 times with 2 to 4 mice undergoing histological evaluation in each experiment.
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Figure 3. Anti-CD40 monoclonal antibody (MoAb)–induced toxicity is mediated by destruction of the colon. BALB/c mice received 750 cGy total
body irradiation and underwent syngeneic bone marrow transplantation followed by daily intraperitoneal injections of either 10 µg of anti-CD40 MoAb
or control serum for 4 days. Mice underwent complete necropsy 24 hours after the last intraperitoneal injection. A and C, BALB/c mice treated with
control serum. Colon has crypts with normal population of goblet cells (g) (A and C, hemotoxylin and eosin stain, original magniﬁcations ×33 and ×66,
respectively). B and D, BALB/c mice treated with anti-CD40 MoAb. Crypts of the colon are diffusely depleted of goblet cells. Many crypts have kary-
omegaly (arrow) and multifocal hyperplasia (h) (B and D, hemotoxylin and eosin stain, original magniﬁcations ×33 and ×66, respectively).
Figure 4. Delayed administration of agonistic anti-CD40 monoclonal
antibody (MoAb) eliminates toxicity. BALB/c mice were given 750 cGy
total body irradiation (TBI) and syngeneic bone marrow transplanta-
tion followed by intraperitoneal injections of either control sera or 10 µg
of anti-CD40 MoAb beginning on day 0 (D0), day 1 (D1), or day 2 (D2)
for a total of 4 injections. All mice receiving anti-CD40 MoAb on day 0
died by day 4, whereas 80% of mice receiving anti-CD40 MoAb on
day 1 died by day 7. Mice receiving anti-CD40 MoAb beginning on
day 2 showed signiﬁcantly increased survival (P < .003) compared with
animals treated on either day 0 or day 1. Data are presented as a combi-
nation of 2 experiments with 4 to 10 mice per group.
Figure 5. Decreased total body irradiation (TBI) eliminates anti-
CD40 monoclonal antibody (MoAb)–induced toxicity. BALB/c mice
were irradiated with 800 cGy, 700 cGy, or 600 cGy; given a syngeneic
bone marrow transplantation; and intraperitoneally injected daily
with 10 µg of anti-CD40 MoAb or control serum. Most mice that
received either 800 cGy or 700 cGy died by day 3, whereas all mice
that received 600 cGy survived (P < .003). Experiments were per-
formed 3 times with 6 to 8 mice per group, and a representative
experiment is shown.
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either anti-CD40 MoAb or control sera (10 µg IP daily for
4 days). Anti-CD40 MoAb–treated mice lacking IFN-γ had
significantly increased survival (P < .0001) compared with
treated wild-type mice (Figure 6). Histological evaluation of
the IFN-γ knockout mice treated with anti-CD40 MoAb
revealed diminished lesions, with mild villous blunting and
fusion in the small intestine and minimal goblet cell depletion
in the colon (Figure 7), compared with similarly treated wild-
type mice (Figures 2 and 3). Thus, gut lesions and associated
morbidity are due, at least in part, to the production of IFN-γ
after CD40 stimulation.
DISCUSSION
We have previously demonstrated that CD40 stimula-
tion, by either antibody or ligand, has been shown to inhibit
the growth of human lymphomas [6] and solid tissue carci-
nomas [9] in vivo without any adverse effects using a
human/mouse xenograft model. In addition, CD40 stimula-
tion has been shown to exert signiﬁcant antitumor effects in
murine leukemia-bearing [15] and lymphoma-bearing [7]
mice without any adverse affects. However, the potential
toxicity of CD40 stimulation by MoAb in the context of
myeloablative therapies, such as TBI, has not been deter-
mined. In this study, we have demonstrated that stimulation
of CD40 using as little as 10 µg of an agonistic murine
MoAb after lethal TBI induces rapid toxicity and death by
4 days in all treated mice. The acute morbidity was the
result of marked destruction of gut tissue, including changes
in the villi, crypts, and goblet cells. Interestingly, this mor-
bidity was not observed in nonirradiated animals, suggesting
that intense myeloablative conditioning plays a role in the
anti-CD40–induced toxicity observed after BMT. Condi-
tioning by either irradiation or chemotherapy triggers an
inﬂammatory process that is characterized by damage to the
intestinal mucosa and by the secretion of proinﬂammatory
cytokines, including IL-1, IL-6, and TNF-α [16]. The gut
lesions observed in our system could be the result of either
anti-CD40 MoAb directly targeting normal gut tissue via
antibody-dependent cell-mediated cytotoxicity (ADCC), the
activation of CD40-expressing normal cell populations (ie,
production of cytokines of monocytes), or both. CD40 is
expressed at low levels on normal gut tissue, and expression
is upregulated in instances of inﬂammation or disease [13].
Therefore, it is possible that the proinﬂammatory cytokines
secreted after lethal TBI upregulate CD40 expression on
gut, thereby making it a target for the antibody, as the
ligand had no adverse effects. To address the role of ADCC
Figure 6. Absence of interferon (IFN)-γ improves survival in anti-
CD40 monoclonal antibody (MoAb)–treated mice. BALB/c wild type
(WT) or BALB/c IFN-γ knockout (KO) mice received 750 cGy total
body irradiation (TBI) and a syngeneic bone marrow transplantation,
followed by daily intraperitoneal injections of 10 µg of anti-CD40
MoAb for 4 days. Mice deﬁcient in IFN-γ showed signiﬁcantly increased
survival (P < .0001) compared with wild-type controls. Data are presented as
a combination of 3 experiments, with 5 to 10 mice per group being used.
Table 2. Decreased Total Body Irradiation (TBI) Diminishes Anti-CD40 MoAb–Induced Gut Damage*
800 cGy TBI 700 cGy TBI 600 cGy TBI
Small Intestine Control Anti-CD40 Anti-CD40 Control Anti-CD40 Anti-CD40 Control Anti-CD40 Anti-CD40
Villous blunting 2 4 3 — 4 3 — — 3
Villous fusion — 4 4 — 4 3 — 2 3
Inflammation 2 3 2 1 2 2 — — —
*BALB/c mice received either 800, 700, or 600 cGy TBI and a syngeneic bone marrow transplantation, followed by daily intraperitoneal injec-
tions of either 10 µg of anti-CD40 monoclonal antibody (MoAb) or control serum for 4 days. Mice were histologically evaluated 24 hours after the
last intraperitoneal injection. Lesions were evaluated and scored as follows: 1, minimal; 2, mild; 3, moderate; 4, severe; —, no signiﬁcant lesion.
Experiments were performed twice with similar results. 
Table 3. Serum INF-γ Levels Increase After TBI and Administration of
Anti-CD40 MoAb*
Conditions IFN-γ Level in Serum, pg/mL
Experiment 1
Control serum <9.4 ± 1.15
10 µg anti-CD40 <9.4 ± 7.57
Experiment 2
750 TBI + control serum <9.4 ± 4.91
750 TBI + 10 µg anti-CD40 123.1 ± 20.8†
750 TBI + 10 µg srmCD40L <9.4 ± 2.54
750 TBI + 100 µg srmCD40L <9.4 ± 4.86
*Either nonirradiated or BALB/c mice receiving 750 cGy total body
irradiation (TBI) were bled for serum following 4 injections of either
agonistic anti-CD40 monoclonal antibody (MoAb), srmCD40L (10 or
100 µg, days 0-4), or control sera and assayed by enzyme-linked
immunosorbent assay. Data are the mean ± SD of 3 mice. Experiments
were performed twice with similar results. INF indicates interferon.
†Signiﬁcantly different (P =.001) from either resting group injected
with anti-CD40 MoAb or from the lethally irradiated group treated
with srmCD40L.
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in toxicity, it would be of interest to evaluate CD40 F(ab′)2
fragments in a syngeneic BMT model. Absence of an Fc
receptor would prevent ADCC from occurring, thereby
potentially eliminating antibody-induced toxicity. However,
pharmacokinetic differences using F(ab′)2 fragments versus
whole antibody and potential differences in signaling capaci-
ties could complicate interpretation of the data. Another
possible mechanism of gut damage may be the activation of
CD40-expressing intestinal macrophages and the release of
inflammatory cytokines after lethal irradiation. IFN-γ
upregulates CD40 expression on macrophages and
enhances the production of large quantities of inﬂammatory
cytokines, such as IL-1β, IL-6, IL-8, IL-12, and TNF, after
stimulation by CD40 [13,14]. IL-12 and IL-18 stimulate the
production of IFN-γ by macrophages [17], leading to
autocrine activation and inﬂammatory cytokine production,
thereby potentially increasing local tissue damage to the gut.
The importance of conditioning is further illustrated by the
absence of toxicity after either delayed CD40 stimulation in
lethally irradiated mice or in mice receiving sublethal doses
of irradiation. Higher doses of irradiation are associated
with increased inflammatory cytokine production and
increased gastrointestinal tract damage [18]. Sublethal irra-
diation could result in lower inﬂammatory cytokine release
and/or less gastrointestinal damage, thereby diminishing
CD40 expression in gut and limiting activation of intestinal
macrophages. Delaying the administration of anti-CD40
MoAb would allow for a subsidence of the burst of inﬂam-
matory cytokines released immediately after TBI. It is possi-
ble that chemotherapeutic agents may also result in
increased toxicity followed with anti-CD40 MoAb treat-
ment, and it would be of interest to address this possibility.
Interestingly, toxicity was not observed after CD40
stimulation by up to 100 µg of srmCD40L in lethally irradi-
ated mice. This result conﬁrms our previous data showing
lack of toxicity with srmCD40L in a murine BMT model
[12]. The differences in toxicity seen after stimulation of
CD40 by agonistic MoAb compared with ligand could be
due to differences in pharmacokinetics. Alternatively, anti-
body-mediated toxicity could be due to ADCC or to more
effective triggering by the antibody on effector cell popula-
tions, such as macrophages.
Figure 7. Absence of interferon (IFN)-γ diminishes gut damage in anti-CD40 monoclonal antibody (MoAb)–treated mice. BALB/c IFN-γ knock-
out mice received 750 cGy total body irradiation and underwent syngeneic bone marrow transplantation, followed by daily intraperitoneal injections
of control serum or 10 µg of anti-CD40 MoAb for 4 days. Mice were killed 24 hours after the last injection. A, Small intestine from a IFN-γ knock-
out mouse that received control serum. Normal villi (v), minimal crypt hyperplasia (c) (hemotoxylin and eosin stain, original magnification
×33). B, Small intestine from a IFN-γ knockout mouse that received anti-CD40 MoAb. Villi (v) are slightly blunted and distorted with a mononu-
clear cell inﬁltrate (arrow) in the lamina propria. Mild crypt cell hyperplasia (c) (hemotoxylin and eosin stain original magniﬁcation ×33). C, Colon
from IFN-γ knockout mouse receiving control serum. Normal crypts with goblet cells (g) (hemotoxylin and eosin stain, original magniﬁcation ×33).
D, Colon from IFN-γ knockout mouse receiving anti-CD40 MoAb. Crypts have mild goblet cell depletion (hemotoxylin and eosin stain, original
magniﬁcation ×66). Experiments were performed twice with 2 or 3 mice per group undergoing histological evaluation.
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After CD40 stimulation by 10 µg of agonistic MoAb,
serum IFN-γ levels were increased 10-fold over either non-
irradiated mice or irradiated mice receiving control serum
or srmCD40L. However, high doses of MoAb in resting
mice resulted in marked increases in IFN-γ levels in the
serum (J.A.H., B.R.B., M.R.A., R.H.W., W.J.M., unpub-
lished data), suggesting a potential role for IFN-γ in the
antitumor effects observed with high doses of anti-CD40
MoAb [7]. In addition, increases of IFN-γ could upregulate
fas on intestinal cells, thereby potentially contributing to the
gut damage observed after CD40 stimulation.
The data using IFN-γ knockout mice indicated that an
absence of IFN-γ has a partially protective effect against anti-
CD40 MoAb–induced toxicity. Because removal of IFN-γ
provided only partial protection from CD40-induced toxicity,
it is possible that there are IFN-γ independent factors con-
tributing to toxicity. A recent study combining the administra-
tion of IL-18 with IL-12 demonstrated acute, lethal toxicity,
with a marked induction of IFN-γ [19]. However, both IFN-γ–
dependent and IFN-γ–independent mechanisms contributed
to the IL-18/IL-12–induced toxicity [19]. IFN-γ primes
monocytes for the secretion of proinﬂammatory cytokines that
could mediate tissue damage [13,14], which may be why some
IFN-γ–deﬁcient mice die after agonistic anti-CD40 MoAb
administration. IFN-γ may also increase CD40 expression in
the gut, making these mice more susceptible to clearance by
the MoAb. We are currently assessing the role of various
proinﬂammatory cytokines, such as IL-12, in toxicity after
CD40 stimulation. Alternatively, other cell populations may
be mediating the observed toxicity after CD40 stimulation. A
recent study showed a fatal toxicity, with similar kinetics to
that observed in our system, after administration of IL-2 and
IL-12 together that was dependent on natural killer (NK)
cells [20], and it would be of interest to assess the role of NK
cells in CD40-induced toxicity. In conclusion, the data pre-
sented here demonstrate that CD40 stimulation via agonistic
MoAb induces rapid and lethal toxicity after lethal TBI and
syngeneic BMT. Clinically, these ﬁndings suggest that cau-
tion must be exercised using CD40 stimulation in patients
receiving intensive myeloablative therapy.
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